Key Takeaways From the U.S. CDC's 2019 Antibiotic Resistance Threats Report for Frontline Providers

Crit Care Med. 2020 Jul;48(7):939-945. doi: 10.1097/CCM.0000000000004371.

Author

Sameer S Kadri¹

Affiliation

¹ Critical Care Medicine Department, NIH Clinical Center, Bethesda, MD.

No abstract available

Publication types

Research Support, N.I.H., Intramural

MeSH terms

Acinetobacter Infections / drug therapy
Candida / drug effects
Candidiasis / drug therapy
Centers for Disease Control and Prevention, U.S.*
Clindamycin / therapeutic use
Drug Resistance, Bacterial*
Drug Resistance, Fungal
Drug Resistance, Multiple, Bacterial
Enterobacteriaceae / drug effects
Enterobacteriaceae Infections / drug therapy
Humans
Methicillin-Resistant Staphylococcus aureus
Pseudomonas Infections / drug therapy
Streptococcal Infections / drug therapy
United States
Vancomycin Resistance

Substances

Clindamycin